Renaissance Technologies
CNTX icon

Renaissance Technologies’s Context Therapeutics CNTX Stock Holding History

Renaissance Technologies’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$291K Sell
967,475
-73,924
-7% -$36.5K ﹤0.01% 2791
2026
Q2 		$577K Buy
1,041,399
+858,400
+469% +$1.74M ﹤0.01% 2549
2026
Q1 		$479K Sell
182,999
-325,330
-64% -$760K ﹤0.01% 2617
2025
Q4 		$747K Buy
508,329
+188,202
+59% +$220K ﹤0.01% 2406
2025
Q3 		$310K Sell
320,127
-43,803
-12% -$35.5K ﹤0.01% 2980
2025
Q2 		$238K Sell
363,930
-61,570
-14% -$44.3K ﹤0.01% 3115
2025
Q1 		$260K Buy
425,500
+87,065
+26% +$75.8K ﹤0.01% 2979
2024
Q4 		$355K Buy
338,435
+272,435
+413% +$471K ﹤0.01% 2987
2024
Q3 		$129K Buy
66,000
+800
+1% +$1.78K ﹤0.01% 3213
2024
Q2 		$131K Buy
65,200
+25,300
+63% +$43.6K ﹤0.01% 3135
2024
Q1 		$55K Buy
39,900
+7,700
+24% +$8.66K ﹤0.01% 3470
2023
Q4 		$36K Buy
32,200
+2,100
+7% +$2.26K ﹤0.01% 3505
2023
Q3 		$45K Buy
30,100
+1,800
+6% +$2.04K ﹤0.01% 3419
2023
Q2 		$45K Buy
28,300
+9,100
+47% +$7.74K ﹤0.01% 3635
2023
Q1 		$11K Sell
19,200
-86,100
-82% -$65.2K ﹤0.01% 3880
2022
Q4 		$69K Sell
105,300
-25,288
-19% -$27.2K ﹤0.01% 3722
2022
Q3 		$145K Buy
+130,588
New +$235K ﹤0.01% 3488
2022
Q2 		– Sell
-20,309
Closed -$44K – 4264
2022
Q1 		$44K Sell
20,309
-44,309
-69% -$93.2K ﹤0.01% 3926
2021
Q4 		$172K Buy
+64,618
New +$322K ﹤0.01% 3564

Other funds holding CNTX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Landscape Capital Management
Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Renaissance Technologies's CNTX Position: Q3 2026 in Review

Renaissance Technologies reduced its Context Therapeutics (CNTX) stake by 7.1% in Q3 2026, selling an estimated $36.5K and leaving 967,475 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #2791.

Renaissance Technologies first reported a position in CNTX in Q4 2021 and has held it in 19 quarters since. The position peaked at $747K in Q4 2025. 47 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

  • Renaissance Technologies held 967,475 shares of Context Therapeutics worth $291K as of Q3 2026.
  • Renaissance Technologies sold 73,924 Context Therapeutics shares in Q3 2026, an estimated $36.5K.
  • Context Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #2791 holding.
  • Renaissance Technologies first reported a position in Context Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Renaissance Technologies's Context Therapeutics position peaked at $747K in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.